The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Novartis, Lilly and Bristol Myers circle a clinical-stage radiopharmaceutical, highlighting deal-structure questions
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 8:39 AM EDT

Novartis, Lilly and Bristol Myers circle a clinical-stage radiopharmaceutical, highlighting deal-structure questions

A clinical-stage radiopharmaceutical startup with no product revenue has drawn interest from three of pharma’s biggest acquirers. Analysts point to the kind of rights structure embedded in a Lilly partnership as a key driver of why large drugmakers would move.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Three major pharmaceutical companies have reportedly been looking at a clinical-stage radiopharmaceutical startup, according to market coverage on Aug. 19, underscoring how deal terms can matter as much as science when large buyers scan early-stage oncology pipelines.

The company at the center of the discussion is described in the report as having no product revenue yet, which is typical of early radiopharmaceutical development where candidates are still working through clinical testing and manufacturing scale-up challenges.

What appears to have sharpened interest is the way rights are arranged inside a partnership involving Eli Lilly. The market report suggests that “the rights structure hiding inside its Lilly partnership” may explain why multiple acquirers are taking a hard look at the asset despite its early stage and lack of revenue.

Radiopharmaceuticals are cancer medicines that combine a targeting component with a radioactive element to deliver therapy directly to tumors. Because the technology depends on both clinical efficacy and logistics (including production and handling), acquirers often pay close attention to who controls manufacturing, commercialization, and development rights by geography and indication.

In this case, the reported interest spans Novartis, Lilly and Bristol Myers, companies that in recent years have all pursued oncology growth strategies that include radioligand approaches and other targeted treatments. The fact that three large buyers are reportedly eyeing the same clinical-stage target suggests the broader market sees potential value in radiopharmaceutical platforms, even before revenue is generated.

Lilly itself did not disclose additional details in the market coverage beyond the existence of the partnership and the suggestion that rights terms are relevant to deal attractiveness. The report also does not lay out specific financial figures, milestone payments, or the exact clinical stage of the radiopharmaceutical program in publicly stated form within the information provided here.

Still, the episode illustrates a familiar pattern in drug M&A: acquirers may move quickly when they believe the legal or operational “path to value” is clearer than it first appears. Rights allocation can determine whether a buyer would gain full control of commercialization, whether development is constrained by partner obligations, and whether the asset could be integrated into an existing platform.

Going forward, investors and industry watchers will likely focus on what rights actually transfer in a potential transaction, the program’s progress in clinical trials, and how responsibilities for manufacturing and regulatory submissions are divided. Without more disclosure on the underlying partnership terms and clinical readouts, it remains uncertain how near the startup is to de-risking efficacy and how large acquirers would structure a deal.

Why It Matters

  • Deal structure can significantly affect acquisition attractiveness for early-stage oncology assets, especially in radiopharmaceuticals where development and commercialization responsibilities can be split across partners.
  • If rights terms create clearer control or easier integration into existing platforms, that can attract multiple large buyers even before revenue exists.
  • The episode reinforces that oncology and targeted radiopharmaceutical development remains an active arena for large pharma, where M&A interest may precede major clinical catalysts.

Sources

Key Facts

  • Market coverage dated Aug. 19, 2026 says a clinical-stage radiopharmaceutical startup drew attention from Novartis, Eli Lilly and Bristol Myers.
  • The startup is described as having no product revenue yet.
  • The report points to a rights structure embedded in an Eli Lilly partnership as a potential explanation for why multiple acquirers are interested.
  • The coverage characterizes the situation as involving a “clinical-stage cancer play” rather than an already commercial product.

Healthcare Related

Novartis, Lilly and Bristol Myers circle a clinical-stage radiopharmaceutical, highlighting deal-structure questions | The Apex Times